ResApp Health Limited and Phenix Health Pty Ltd. have signed a software licensing agreement to use ResApp's acute respiratory diagnostic test, ResAppDx-EU, in Phenix's telehealth smartphone app. ResAppDx-EU is approved by the Therapeutics Goods Administration (TGA) in Australia and is CE Marked in Europe as an aid for clinicians in the diagnosis of a range of respiratory diseases. The two-year, non-exclusive commercial software licensing agreement allows Phenix to use ResAppDx-EU in their telehealth smartphone app within Australia from July 1, 2020. The per test license fee received by ResApp is in the previously targeted range of $5 to $10. The licence may be extended beyond the initial two-year term by mutual agreement and either party may terminate the licence by providing 60 days written notice.